tiprankstipranks
Trending News
More News >

Calliditas Therapeutics downgraded to Neutral from Buy at Citi

Citi downgraded Calliditas Therapeutics (CALT) to Neutral from Buy with a $39 price target after Asahi Kasei (AHKSY) announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue